THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International (OTC Markets: TSOI) announced the release of a video by its spin-off, Campbell Neurosciences, exploring the diagnosis and prevention of suicide, which has surged during the COVID-19 pandemic. The company has developed the Campbell Score™, a clinically-validated diagnostic test for suicidal ideations, and various regenerative intervention methodologies. Key figures in the project include Howard Leonhardt and Dr. James Veltmeyer. TSOI has also completed two clinical trials and licensed ten patients to Campbell.

Therapeutic Solutions International, Inc. (TSOI) filed a new patent utilizing tolerogenic dendritic cells from umbilical cord blood to suppress Parkinson's Disease in animal models. The modified StemVacs dendritic cells demonstrated the ability to reduce brain inflammation and preserve dopaminergic neurons, a key factor in Parkinson's Disease, which affects approximately 1 million Americans and costs the healthcare system about $52 billion annually. The company emphasizes the immunological component of Parkinson's and aims to combine regenerative cells with immune response repair as a treatment strategy.

Therapeutic Solutions International (TSOI) has initiated pilot implementation of the Campbell Score™ blood-based suicide prediction marker, in collaboration with Concierge Medical & Wellness Inc in San Diego. This innovative tool aims to assist psychiatrists in quantifying suicide risk and is based on positive clinical trial results indicating higher scores for patients with suicidal tendencies. The company plans to further develop this tool with potential FDA clearance and insurance reimbursement in the future.

Therapeutic Solutions International (OTC Markets: TSOI) has released new preclinical data showing the efficacy of JadiCell Universal Donor stem cells in reducing neuroinflammation and restoring cognitive function after brain damage caused by post-COVID-19. Key findings include a significant decrease in astrogliosis and improvements in memory as per established tests. A recent clinical trial demonstrated increased patient survival rates (91% vs 42%) and quicker recovery times, with JadiCell infusions indicated as safe. The company aims to further explore treatments for COVID-19-related neurological issues.

Therapeutic Solutions International (OTC Markets: TSOI) announced findings validating its patent application, demonstrating a synergy between low dose naltrexone and T regulatory cell stimulators. In experiments, low dose naltrexone combined with interleukin-2 effectively reduced schizophrenic-like behavior in an animal model. The company aims to file an IND with the FDA soon, highlighting the importance of immune-brain interactions and repositioning safe drugs. Leadership expressed enthusiasm about leveraging immune modulation for treating schizophrenia, emphasizing the potential for innovative therapies.

Therapeutic Solutions International (TSOI) announced that its subsidiary, Campbell Neurosciences, achieved promising results in an animal model of schizophrenia using tolerogenic dendritic cells. These cells suppressed various neurological symptoms and increased T regulatory cell counts. Dr. James Veltmeyer emphasized the potential of immunology in treating neurological diseases. Campbell Neurosciences focuses on combating suicide through immunology and regenerative psychiatry, with a clinically validated blood test for suicidal ideation, the Campbell Score, and 13 patent applications covering diagnostics and therapies.

Therapeutic Solutions International (OTC Markets: TSOI) reported promising results from experiments showcasing the synergy between its StemVacs-V iPSC immunotherapy and traditional cancer treatment methods. The combination generated robust immunological memory against tumor cells, potentially converting 'cold tumors' into 'hot tumors' responsive to immunotherapy. The firm is exploring partnerships to expand its therapeutic applications, including synergy with oncolytic viruses and CAR-T therapies. The breakthrough could significantly enhance treatment options within the $100 billion cancer immunotherapy market.

Therapeutic Solutions International (OTC Markets: TSOI) has released significant research indicating that stem cell therapy may alleviate schizophrenia symptoms through the induction of T regulatory cells. Their findings show enhanced levels of anti-inflammatory cytokines and FoxP3-expressing cells in treated mice. The team aims to file an investigational new drug (IND) application with the FDA for clinical trials. CEO Kalina O'Connor emphasizes the urgency of addressing this condition, while CMO Dr. James Veltmeyer advocates for a new approach to treatment based on immunology.

On May 24, 2021, Therapeutic Solutions International (OTC Markets: TSOI) announced promising data regarding its tumor blood vessel-killing vaccine, StemVacs-V iPSC. This data, essential for an upcoming FDA Investigational New Drug (IND) filing, showcases synergy with specific immunological adjuvants. The vaccine is designed for superior potency and reproducibility, derived from a single inducible pluripotent stem cell donor. The company emphasizes its commitment to enhancing therapeutic efficacy in cancer treatment and has filed a patent application to protect its innovative approaches.